A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 11, 2022

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2037

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL

B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell

Autologous 2nd generation BCMA-directed CAR-T cells, single infusion intravenously

Trial Locations (1)

RECRUITING

Institute of Hematology and Blood Diseases Hospital, Tianjin

All Listed Sponsors

lead

Shanghai AbelZeta Ltd.

INDUSTRY